Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.
2.

[Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin].

Veillon P, Payan C, Gaudy C, Goudeau A, Lunel F.

Pathol Biol (Paris). 2004 Nov;52(9):505-10. French.

PMID:
15531113
3.
4.

Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.

El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, Hotta H.

Microbiol Immunol. 2011 Jun;55(6):418-26. doi: 10.1111/j.1348-0421.2011.00331.x.

7.

Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon.

Kobayashi M, Watanabe K, Ishigami M, Murase K, Ito H, Ukai K, Yano M, Takagi K, Hattori M, Kakumu S, Yoshioka K.

Am J Gastroenterol. 2002 Apr;97(4):988-98.

PMID:
12003437
8.

NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.

Bouzgarrou N, Hassen E, Mahfoudh W, Gabbouj S, Schvoerer E, Ben Yahia A, Ben Mami N, Triki H, Chouchane L.

J Med Virol. 2009 Dec;81(12):2021-8. doi: 10.1002/jmv.21641.

PMID:
19856481
9.

Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.

Saito T, Ito T, Ishiko H, Yonaha M, Morikawa K, Miyokawa A, Mitamura K.

Am J Gastroenterol. 2003 Jun;98(6):1377-83.

PMID:
12818284
10.
11.

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2006 Jan;78(1):83-90.

PMID:
16299715
13.

Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment.

Torres-Puente M, Cuevas JM, Jiménez-Hernández N, Bracho MA, García-Robles I, Carnicer F, del Olmo J, Ortega E, Moya A, González-Candelas F.

J Med Virol. 2008 Feb;80(2):247-53.

PMID:
18098147
14.

Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?

Squadrito G, Raffa G, Restuccia T, Pollicino T, Brancatelli S, Raimondo G.

J Viral Hepat. 2002 Sep;9(5):360-9.

PMID:
12225331
15.

Mutations in the nonstructural region 5B of hepatitis C virus genotype 1b: their relation to viral load, response to interferon, and the nonstructural region 5A.

Watanabe K, Yoshioka K, Yano M, Ishigami M, Ukai K, Ito H, Miyata F, Mizutani T, Goto H.

J Med Virol. 2005 Apr;75(4):504-12.

PMID:
15714488
16.
17.

Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b.

Hofgärtner WT, Polyak SJ, Sullivan DG, Carithers RL Jr, Gretch DR.

J Med Virol. 1997 Oct;53(2):118-26.

PMID:
9334922
18.

Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha.

Gerotto M, Dal Pero F, Sullivan DG, Chemello L, Cavalletto L, Polyak SJ, Pontisso P, Gretch DR, Alberti A.

J Viral Hepat. 1999 Sep;6(5):367-72.

PMID:
10607252
19.

Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.

Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P, Raimondo G, Pol S, Bréchot C.

Gastroenterology. 1997 Aug;113(2):567-72.

PMID:
9247477
20.

Supplemental Content

Support Center